메뉴 건너뛰기




Volumn 107, Issue 11, 2012, Pages 1820-1825

VeriStrat ® has prognostic value in advanced stage NSCLC patients treated with erlotinib and sorafenib

Author keywords

erlotinib; lung cancer; personalised therapy; proteomics; serum biomarker; sorafenib

Indexed keywords

ERLOTINIB; SORAFENIB;

EID: 84870065029     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.470     Document Type: Article
Times cited : (36)

References (27)
  • 1
    • 84870063166 scopus 로고    scopus 로고
    • Bevacizumab/erlotinib (BEER) as first-line treatment for untreated, advanced non-squamous non-small cell lung cancer (NSNSCLC
    • Akerley WL, Rich NT, Egbert L, Harker WG, Van Duren T, Smit J, Hoffman JM (2010) Bevacizumab/erlotinib (BEER) as first-line treatment for untreated, advanced non-squamous non-small cell lung cancer (NSNSCLC). J Clin Oncol 28(15 Suppl): e18008
    • (2010) J Clin Oncol , vol.28 , Issue.15 SUPPL.
    • Akerley, W.L.1    Rich, N.T.2    Egbert, L.3    Harker, W.G.4    Van Duren, T.5    Smit, J.6    Hoffman, J.M.7
  • 2
    • 77649114574 scopus 로고    scopus 로고
    • Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503
    • Amann JM, Lee JW, Roder H, Brahmer J, Gonzalez A, Schiller JH, Carbone DP (2010) Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503. J Thorac Oncol 5: 169-178
    • (2010) J Thorac Oncol , vol.5 , pp. 169-178
    • Amann, J.M.1    Lee, J.W.2    Roder, H.3    Brahmer, J.4    Gonzalez, A.5    Schiller, J.H.6    Carbone, D.P.7
  • 3
    • 0022480472 scopus 로고
    • Serum amyloid A (SAA) variations in patients with cancer: Correlation with disease activity, stage, primary site, and prognosis
    • Biran H, Friedman N, Neumann L, Pras M, Shainkin-Kestenbaum R (1986) Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J Clin Pathol 39: 794-797
    • (1986) J Clin Pathol , vol.39 , pp. 794-797
    • Biran, H.1    Friedman, N.2    Neumann, L.3    Pras, M.4    Shainkin-Kestenbaum, R.5
  • 4
    • 11344268358 scopus 로고    scopus 로고
    • Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor
    • Camp ER, Summy J, Bauer TW, Liu W, Gallick GE, Ellis LM (2005) Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11: 397-405
    • (2005) Clin Cancer Res , vol.11 , pp. 397-405
    • Camp, E.R.1    Summy, J.2    Bauer, T.W.3    Liu, W.4    Gallick, G.E.5    Ellis, L.M.6
  • 5
    • 77955115579 scopus 로고    scopus 로고
    • Serum proteomic prediction of outcomes in advanced NSCLC patients treated with erlotinib or placebo in the NCIC CTG BR.21 trial
    • abstract number 2030. 2010a
    • Carbone DP, Ding K, Roder H, Tsao M, Shepherd FA, Seymour L (2010a) Serum proteomic prediction of outcomes in advanced NSCLC patients treated with erlotinib or placebo in the NCIC CTG BR.21 trial. J Thorac Oncol 5(Suppl 1): abstract number 2030. 2010a
    • (2010) J Thorac Oncol , vol.5 , Issue.SUPPL. 1
    • Carbone, D.P.1    Ding, K.2    Roder, H.3    Tsao, M.4    Shepherd, F.A.5    Seymour, L.6
  • 10
    • 84870060107 scopus 로고    scopus 로고
    • Serum proteomic classifier for patients with advanced non-small cell lung cancer (NSCLC) treated with erlotinib and bevacizumab in the first line: Pooled analysis of phase II trials SAKK 19/05 and NTR528
    • Presented at Geneva, Switzerland
    • Gautschi O, Dingemans AC, Crowe S, Roder H, Zappa F, Pless M, Brustche M, Peters S, Carbone D, Smit EF (2012) Serum proteomic classifier for patients with advanced non-small cell lung cancer (NSCLC) treated with erlotinib and bevacizumab in the first line: pooled analysis of phase II trials SAKK 19/05 and NTR528. Presented at III European Lung Cancer Conference. (Geneva, Switzerland
    • (2012) III European Lung Cancer Conference
    • Gautschi, O.1    Dingemans, A.C.2    Crowe, S.3    Roder, H.4    Zappa, F.5    Pless, M.6    Brustche, M.7    Peters, S.8    Carbone, D.9    Smit, E.F.10
  • 11
    • 84655175680 scopus 로고    scopus 로고
    • Prospective studies with proteomics
    • Presented at 4 August 2009 San Francisco
    • Gregorc V (2009) Prospective studies with proteomics. Presented at 13th World Conference on Lung Cancer. ; 4 August 2009; San Francisco
    • (2009) 13th World Conference on Lung Cancer
    • Gregorc, V.1
  • 13
    • 79957823572 scopus 로고    scopus 로고
    • Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): A double-blind, placebo-controlled, phase 3 trial
    • Herbst RS, Ansari R, Bustin F, Flynn P, Hart L, Otterson GA, Vlahovic G, Soh CH, O'Connor P, Hainsworth J (2011) Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. Lancet 377: 1846-1854
    • (2011) Lancet , vol.377 , pp. 1846-1854
    • Herbst, R.S.1    Ansari, R.2    Bustin, F.3    Flynn, P.4    Hart, L.5    Otterson, G.A.6    Vlahovic, G.7    Soh, C.H.8    O'Connor, P.9    Hainsworth, J.10
  • 14
    • 19844364244 scopus 로고    scopus 로고
    • Angiogenesis and lung cancer: Prognostic and therapeutic implications
    • Herbst RS, Onn A, Sandler A (2005) Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23: 3243-3256
    • (2005) J Clin Oncol , vol.23 , pp. 3243-3256
    • Herbst, R.S.1    Onn, A.2    Sandler3
  • 15
    • 84870060110 scopus 로고    scopus 로고
    • Pretreatment sera from NSCLC patients with different outcomes on EGFR-TKI therapy differentially affects sensitivity of lung cancer cell lines to EGFR-TKIs
    • 2-6 April 2011 Orlando, Florida. AACR: Philadelphia (PA), abstract number LB-306
    • Hunsucker SW, Grigorieva J, Helfrich BA, Allen J, Bunn PA, Roder H (2011) Pretreatment sera from NSCLC patients with different outcomes on EGFR-TKI therapy differentially affects sensitivity of lung cancer cell lines to EGFR-TKIs. Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research. ; 2-6 April 2011; Orlando, Florida. AACR: Philadelphia (PA), abstract number LB-306
    • (2011) Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research
    • Hunsucker, S.W.1    Grigorieva, J.2    Helfrich, B.A.3    Allen, J.4    Bunn, P.A.5    Roder, H.6
  • 16
    • 24044445220 scopus 로고    scopus 로고
    • Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio
    • Kokubun M, Imafuku Y, Okada M, Ohguchi Y, Ashikawa T, Yamada T, Yoshida H (2005) Serum amyloid A (SAA) concentration varies among rheumatoid arthritis patients estimated by SAA/CRP ratio. Clin Chim Acta 360: 97-102
    • (2005) Clin Chim Acta , vol.360 , pp. 97-102
    • Kokubun, M.1    Imafuku, Y.2    Okada, M.3    Ohguchi, Y.4    Ashikawa, T.5    Yamada, T.6    Yoshida, H.7
  • 19
    • 84869861682 scopus 로고    scopus 로고
    • SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors
    • e-pub ahead of print 4 July 2012 doi: 10.1016/j.jprot.2012.06.022
    • Milan E, Lazzari C, Anand S, Floriani I, Torri V, Sorlini C, Gregorc V, Bachi A (2012) SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. J Proteomics; e-pub ahead of print 4 July 2012; doi: 10.1016/j.jprot.2012.06.022
    • (2012) J Proteomics
    • Milan, E.1    Lazzari, C.2    Anand, S.3    Floriani, I.4    Torri, V.5    Sorlini, C.6    Gregorc, V.7    Bachi, A.8
  • 20
    • 33947498978 scopus 로고    scopus 로고
    • Molecular predictors of response to epidermal growth factor receptor antagonists in non-smallcell lung cancer
    • Sequist LV, Bell DW, Lynch TJ, Haber DA (2007) Molecular predictors of response to epidermal growth factor receptor antagonists in non-smallcell lung cancer. J Clin Oncol 25: 587-595
    • (2007) J Clin Oncol , vol.25 , pp. 587-595
    • Sequist, L.V.1    Bell, D.W.2    Lynch, T.J.3    Haber, D.4
  • 24
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van GM, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3    Wanders, J.4    Kaplan, R.S.5    Rubinstein, L.6    Verweij, J.7    Van Gm Van Oosterom, A.T.8    Christian, M.C.9    Gwyther, S.G.10
  • 26
    • 80055090025 scopus 로고    scopus 로고
    • Most random gene expression signatures are significantly associated with breast cancer outcome
    • Venet D, Dumont JE, Detours V (2011) Most random gene expression signatures are significantly associated with breast cancer outcome. PLoS Comput Biol 7: e1002240
    • (2011) PLoS Comput Biol , vol.7
    • Venet, D.1    Dumont, J.E.2    Detours, V.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.